Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc.

UDENYCA, a biosimilar to Neulasta (pegfilgrastim), expands the company’s portfolio of FDA-approved products and accelerates Accord BioPharma’s growth in the biosimilar industry.

By acquiring UDENYCA, Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, will continue to make this treatment available to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Since the brand’s commercial launch, more than 300,000 patients are estimated to have been treated with UDENYCA and over 1.4 million units have been sold.

The acquisition not only expands Accord BioPharma’s product offerings, but also brings a wealth of talent from Coherus BioSciences. Key Coherus employees across multiple functions, including Sales, Marketing, Finance, Supply Chain, and Quality and Manufacturing, will join Accord BioPharma, playing a crucial role in supply and services continuity/transition and expanding the company’s work around UDENYCA.

“The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavor to innovate and expand in the biosimilar space,” said Chrys Kokino, U.S. President of Accord. “We are delighted to welcome talented employees from Coherus, whose historical knowledge and expertise will complement that of our existing team, making us stronger and better equipped to achieve our goals with UDENYCA.”

“We are energized by this addition to Accord BioPharma’s portfolio because it exemplifies our commitment to improving patient access to high-quality treatments that effectively meet the needs of both patients and healthcare providers,” said Binish Chudgar, Executive Chairman and Managing Director of Intas Pharmaceuticals. “We are pleased with the successful completion of this agreement and are excited about the future opportunities it brings for Accord BioPharma in the U.S. market.”